Sfoglia per AUTORE
BORELLI B
Collezione AO Cuneo

  

Items : 8

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

2019
AO Cuneo

Fontanini G; Lonardi S; Sensi E; Tonini G; Schirripa M; Granetto C; Delfanti S; Di Donato S; Casagrande M; Gemma D; Borelli B; Allegrini G; Murgioni S; Antoniotti C; Dell'Aquila E; Masi G; Salvatore L; Aprile G; Bergamo F; Marmorino F; Cremolini C; Boni L; Falcone A;

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C;

Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib in Annals of Oncology

2019
AO Cuneo
AOU Città della Salute di Torino

Ricci V; Falletta A; Granetto C; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano M; Zucchelli G; Marmorino F; Rossini D; Aprile G; Casagrande M; Lonardi S; Murgioni S; Dell'Aquila E; Tomasello G; Moretto R; Antoniotti C; Borelli B; Urbano F; Ronzoni M; Zaniboni A; Manglaviti S; Buonadonna A; Ritorto G; Masi G; Allegrini G; et alii...

Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies in Journal of Clinical Oncology

2019
AO Cuneo
AOU Città della Salute di Torino

Zucchelli G; Moretto R; Schirripa M; Intini R; Rossini D; Santini D; Pizzo C; Antoniotti C; Borelli B; Marmorino F; Urbano F; Burgio V; Libertini M; Prisciandaro M; Buonadonna A; Bustreo S; Allegrini G; Ricci V; Cremolini C; Falcone A;

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

2018
AOU Città della Salute di Torino
AO Cuneo

Boni L; Zagonel V; Di Donato S; Ricci V; Allegrini G; Buonadonna A; Racca P; Zaniboni A; Tomasello G; Ronzoni M; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Lonardi S; Antoniotti C; Del Re M; Cremolini C; Falcone A; Danesi R;

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. in ESMO open / ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

2018
AO Cuneo

Falcone A; Boni L; Cremolini C; Delliponti L; Vitello S; Antonuzzo L; Martinelli E; Vannini F; Marsico VA; Colombo C; Granetto C; Leone F; Passardi A; Boccaccino A; Pella N; Di Battista M; Martignetti A; Zaniboni A; Zucchelli G; Salvatore L; Rossini D; Marmorino F; Burgio V; Masi G; Pietrantonio F; Bonetti A; Antoniotti C; Lonardi S; Borelli B; et alii...

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies in Journal of Clinical Oncology

2016
AO Cuneo

Casagrande M; Moretto R; Loupakis F; Cremolini C; Masi G; Borelli B; Lonardi S; Marsico VA; Ferrari L; Ricci V; Grande R; Tomasello G; Ronzoni M; Allegrini G; Tonini G; Mancini ML; Zaniboni A; Chiara S; Carlomagno C; Falcone A;